CN
CN
|
3SBio Group has always been committed to solving the problem of clinical drug use for patients, constantly conquering the challenges of the disease, using high-quality drugs to improve the quality of life of patients, and working hard for the benefit of human health. |
Beginning in 1993, 3SBio dares to innovate and pursues excellence. After 20 years of rapid development, 3SBio Group has now become a leading Chinese biopharmaceutical company that integrates R&D, production and sales, and has achieved great success in the international market.
In 1993, Shenyang Sunshine Pharmaceuticals CO., Ltd was founded by the 58-year-old Major General Lou Dan and his team. Lou Dan is a member of the National Medical Review Committee, a well-known bioengineering medical expert and the previous director of the Institute of Microbiology and Immunology of Shenhou Military Medical Research Institute and served as the chairman and president as well as chief engineer of the company.
In April 1995, Intefen was approved to be manufactured by NMPA.
In December 1995, Intefen was launched and is included in the National Medical Insurance Catalogue as a Category B drug.
In June 1995, NMPA production approval documents were obtained for Inleusin.
This product was launched in March 1996 and is included in the National Medical Insurance Catalogue as a Category B drug.
In 1998, EPIAO was marketed with approval of the NMPA, which was the first rhEPO products marketed in China. Since 2002, it has been the leading brand of China’s erythropoin market. It is included in the National Medical Insurance Catalogue as a Category B drug.
NMPA production approval documents were obtained for SEPO in 2001.It was listed in 2002 and is included in the National Medical Insurance Catalogue as a Category B drug. In 2014, SEPO was rated as famous trademark by Guangdong Province Administration for Industry & Commerce. SPARIN was approved by the NMPA and listed in 2002.
In 2005, TPIAO was listed and has been approved by the NMPA for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (ITP) (approved in 2010), which is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.
YISAIPU was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 2 kinds of indications were approved by the NMPA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.
Qiming granule is an exclusive formula of TCM, indicated for the treatment of Type 2 diabetic retinopathy.
It is the project achievement of Science and Technology Development during the “9th Five-Year Plan” and “10th Five-Year Plan” and support plan during the “11th Five-Year Plan” and was identified as a national protected traditional Chinese medicine by NMPA in 2013. Qiming granule is the first NMPA-approved new Chinese medicine for treatment of diabetic retinopathy and is included in the National Medical Insurance Catalogue as a Category B drug of Chinese patent medicine.
These facilities have been certified by NMPA and comply with the major international regulatory guidelines (including regulations of the cooperation plan between European Food and Drug Administration and International Drug Inspection).These facilities have increased the production capacity of EPIAO and TPIAO by approximately four times.
It is the project achievement of Science and Technology Development during the “9th Five-Year Plan” and “10th Five-Year Plan” and support plan during the “11th Five-Year Plan” and was identified as a national protected traditional Chinese medicine by NMPA in 2013.Qiming granule is the first NMPA-approved new TCM drug for treatment of diabetic retinopathy and is included in the National Medical Insurance Catalogue as a Category B drug of Chinese patent medicine.
On October 11, 2016, we have entered into an exclusive license agreement with AstraZeneca to obtain the commercial rights of Byetta and Bydureon in China, which are valid for 20 years.
